Wall Street analyst estimates for Harmony Biosciences Holdings, Inc. (HRMY): consensus price target, buy/hold/sell recommendations and forecasts for revenue and EPS for the upcoming fiscal years.
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc.
Consensus price target
$48.67 (+31 % vs price $37.02)
between $34.00 and $70.00 · 7 targets published in the last quarter
Closing price, Nov 3
A twelve-month target is not a fair value: compare it with the range in the Valuation tab.
Revenue and EPS estimates
| Fiscal year | Revenue (average) | Revenue (low – high) | EPS (average) | Analysts |
|---|---|---|---|---|
| 2026E | $1.0B | $1.0B – $1.0B | $3.91 | 7 |
| 2027E | $1.2B | $1.1B – $1.3B | $4.45 | 6 |
| 2028E | $1.3B | $1.0B – $1.6B | $4.94 | 11 |
Figures in USD · consensus as of November 2, 2026
Analyst Consensus
| Strong Buy | 0 |
| Buy | 8 |
| Hold | 3 |
| Sell | 2 |
| Strong Sell | 0 |
| Total analysts | 13 |
| Avg rating (−2 sell to +2 buy) | 0.46 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-04 | $1.09 | ||
| 2026-08-04 | $1.28 | $0.96 | +33.9% |
| 2026-05-07 | $0.55 | $0.76 | -27.6% |
| 2026-02-24 | $0.38 | $0.84 | -54.8% |
| 2025-11-04 | $0.87 | $0.92 | -5.4% |
| 2025-08-05 | $0.68 | $0.78 | -12.8% |
| 2025-05-06 | $0.78 | $0.59 | +32.2% |
| 2025-02-25 | $0.85 | $0.74 | +14.9% |
Valuation Ratios
| P/E Ratio | 12.02 |
| Price / Book | 2.14 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | $6.0M | $159.7M | $305.4M | $437.9M | $582.0M | $714.7M | $868.5M |
| Cost of Revenue | $184,000 | $1.6M | $27.7M | $55.5M | $83.5M | $121.2M | $156.8M | $198.3M |
| Gross Profit | -$184,000 | $4.4M | $132.0M | $249.9M | $354.4M | $460.8M | $557.9M | $670.1M |
| Research & Development | $12.4M | $69.6M | $19.4M | $30.4M | $70.9M | $76.1M | $145.8M | $189.6M |
| Selling, General & Admin | $29.1M | $80.7M | $95.6M | $132.0M | $163.3M | $192.7M | $221.3M | $272.0M |
| Operating Expenses | $41.4M | $150.3M | $115.0M | $162.4M | $234.2M | $268.8M | $367.1M | $461.6M |
| Operating Income | -$41.4M | -$145.9M | $17.0M | $87.5M | $120.2M | $192.0M | $190.8M | $208.5M |
| EBITDA | -$41.3M | -$142.7M | $1.5M | $80.5M | $146.9M | $221.5M | $233.4M | $255.0M |
| Interest Expense | 0 | $6.1M | $28.2M | $24.2M | $18.8M | $23.8M | $17.5M | $14.6M |
| Pre-tax Income | -$39.9M | -$152.0M | -$36.9M | $37.4M | $104.7M | $173.4M | $191.8M | $215.1M |
| Income Tax | 0 | 0 | 0 | $2.8M | -$76.8M | $44.5M | $46.3M | $56.4M |
| Net Income | -$39.9M | -$152.0M | -$36.9M | $34.6M | $181.5M | $128.9M | $145.5M | $158.7M |
| EPS | -$1.42 | -$2.94 | -$1.12 | $0.60 | $3.07 | $2.17 | $2.56 | $2.76 |
| EPS (Diluted) | -$1.42 | -$2.94 | -$1.10 | $0.58 | $2.97 | $2.13 | $2.51 | $2.71 |
| Shares Outstanding (Diluted) | 49.2 M | 63.7 M | 57.8 M | 59.2 M | 61.1 M | 60.4 M | 57.9 M | 58.5 M |
Price
| Price | $37.02 (closing price, November 3, 2026) |
| Market Cap | $2.2B |
| Exchange | NASDAQ |
| Country | US |
Related companies: VRTX · 0QZU.L · REGN · MRNA · 0R2M.L · ARGX · 0QNO.L · RVMD
Explore sector: Healthcare · Biotechnology
More sections of HRMY: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks